Welcome to our dedicated page for iBio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on iBio stock.
iBio, Inc. (symbol: IBIO) is a specialized contract development and manufacturing organization (CDMO) that facilitates the journey from early product selection to market launch. Situated within the healthcare sector, iBio is renowned for its plant-based protein expression technologies, which are pivotal in developing vaccines, therapeutic proteins, and biopharmaceutical products.
The company operates through two primary segments: Biopharmaceuticals and Bioprocessing. iBio's Biopharmaceuticals segment focuses on the development and commercialization of product candidates aimed at addressing critical health issues such as fibrotic diseases, cancers, and infectious diseases. The Bioprocessing segment, meanwhile, involves comprehensive manufacturing and regulatory support services offered through iBio CDMO.
iBio's technology platform and state-of-the-art facilities are designed to expedite development processes, providing significant time and cost advantages over traditional approaches. The company boasts a team of skilled protein scientists, microbiologists, manufacturing experts, and regulatory professionals committed to delivering seamless scale-up from preclinical to commercial production.
Recent achievements include advancements in biotherapeutics and diagnostic products, showcasing iBio's capability to innovate and respond to global health challenges effectively. The company also maintains strategic partnerships that bolster its research and development efforts, ensuring consistent progress in the healthcare landscape.
With its focus on rapid manufacturing support and regulatory compliance, iBio stands out as a reliable partner for clients seeking efficient pathways to clinical and commercial success.
iBio, Inc. (NYSEA:IBIO), a leader in biopharmaceuticals, announced that its Chairman & CEO, Tom Isett, and CSO, Martin Brenner, will engage in a fireside chat at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 10:00 a.m. ET. This event will focus on the innovative FastPharming Manufacturing System® and the company’s advancements in biopharmaceutical development. The chat will be broadcast live on the company’s website and archived for future access.
iBio, Inc. (NYSEA:IBIO) is set to report its fiscal fourth quarter and full year 2021 financial results on September 27, 2021, before market open. Management will host a webcast and conference call at 8:30 a.m. ET to discuss the results and provide a corporate update. iBio is renowned for its FastPharming Manufacturing System®, focusing on sustainable, plant-based biopharmaceuticals. The company develops proprietary treatments for cancers, fibrotic, and infectious diseases while offering FastPharming Contract Development and Manufacturing Services.
iBio, Inc. (NYSEA:IBIO) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. A pre-recorded presentation by iBio will be available on demand for registered attendees and on their website from September 13. iBio specializes in sustainable, plant-based pharmaceuticals through its FastPharming Manufacturing System®, developing treatments for cancer, fibrotic, and infectious diseases, while also providing contract development services.
iBio, Inc. (NYSE:IBIO) has appointed William D. (Chip) Clark to its Board of Directors, bringing over 30 years of biotechnology experience, particularly in immuno-oncology. His prior leadership at Genocea was marked by a pivotal shift to immuno-oncology, and his insights are expected to support the advancement of IBIO-101 and other therapies. The company aims to leverage its FastPharming Manufacturing System to enhance cancer drug development. The press release also highlights ongoing forward-looking statements regarding regulatory approvals and marketplace acceptance.
iBio licenses a novel antibody targeting regulatory T cells through a worldwide exclusive agreement with RubrYc Therapeutics for RTX-003, enhancing its oncology pipeline. The partnership includes options for additional antibodies from RubrYc's AI-based platform. iBio has acquired an equity stake in RubrYc and is committed to further investment. Preclinical data shows RTX-003 effectively depletes Tregs without blocking IL-2 signaling, promising strong anti-tumor responses. iBio plans to advance RTX-003 to clinical studies as IBIO-101, with IND-enabling studies expected by mid-2022.
iBio announced positive results from preclinical studies of its COVID-19 vaccine candidate, IBIO-202, which targets the nucleocapsid protein of SARS-CoV-2. The studies revealed a strong antigen-specific memory T-cell response, suggesting that IBIO-202 may complement existing spike protein-directed vaccines by enhancing durability against emerging variants. The N protein is more conserved, showing 90% amino acid homology, and can induce T-cell proliferation. Ongoing characterization studies aim to further explore the vaccine's potential.
iBio, a biotech innovator, announced the addition of three anti-cancer targets to its pipeline. This follows its recent drug discovery capability expansion via the FastPharming Protein Expression System. iBio has partnered with FairJourney Biologics for antibody optimization, utilizing their novel display technologies. The collaboration aims to enhance the development of differentiated cancer therapeutic antibodies and improve the process of moving from concept to clinical trials. iBio leverages Glycaneering Technologies to optimize antibody-dependent cell-mediated cytotoxicity.
iBio, Inc. (NYSEA:IBIO) has appointed Evert (Eef) Schimmelpennink to its Board of Directors, effective immediately. Schimmelpennink brings over 20 years of experience in corporate development and biopharmaceutical operations, previously serving as CEO of Pfenex Inc., which was acquired for $516 million in 2020. His expertise aligns with iBio's strategy to enhance its drug discovery capabilities and leverage its patented FastPharming System for efficient biopharmaceutical development. This leadership transition aims to catalyze growth and innovative solutions in addressing healthcare needs.
iBio, a biotech innovator and biologics contract manufacturer, will present a business update at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 4:00 p.m. Eastern Time. This presentation underscores iBio's commitment to advancing its plant-based biologics manufacturing, particularly through its FastPharming® System, which enables rapid delivery of monoclonal antibodies and vaccines. The event will be webcast live and available for later viewing on iBio's website under the Investors section.
iBio reported fiscal Q3 2021 revenues of approximately $0.8 million, up from $0.1 million year-over-year, with a gross profit of $0.3 million. The net loss attributable to stockholders was about $7.7 million, or $0.04 per share, compared to a $4.7 million loss in Q3 2020. iBio is advancing its COVID-19 vaccine candidates IBIO-201 and IBIO-202 while planning to establish drug discovery capabilities in San Diego targeting monoclonal antibodies. The company also expanded its Bioanalytical Services and expects sufficient resources to fund operations through March 2023.
FAQ
What is the current stock price of iBio (IBIO)?
What is the market cap of iBio (IBIO)?
What does iBio, Inc. specialize in?
What are the main segments iBio operates in?
What services does iBio offer?
Who comprises iBio’s team?
What are the key areas iBio's products target?
How does iBio's technology platform benefit clients?
What recent achievements has iBio made?
What is iBio CDMO?
Does iBio collaborate with other organizations?
How can I contact iBio for investor or media relations?
